Panelists reached a consensus that pirfenidone should be permanently discontinued if a patient exhibits > 3 but ≤5 × upper limit of normal (ULN) alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) accompanied by symptoms or hyperbilirubinemia. This evidence concerns the gene GPT and Hyperbilirubinemia.